

Date of Preparation: 7/20/2009

Appears this way on original.

Signature

Abraham Thomas, MD, MPH

Office Address:  
Division of Endocrinology  
3031 West Grand Blvd,  
Suite 800  
Detroit, Michigan 48202

(b) (6)

Telephone: 313-916-3761  
Fax: 313-916-6992  
Email: athomas3@hfhs.org

(b) (6)

#### EDUCATION:

1985	A.B., Columbia University, Columbia College.
1989	M.D., Columbia University, College of Physicians & Surgeons
2004	M.P.H., Harvard School of Public Health

#### TRAINING:

1989 June-1990 June	Intern in Internal Medicine, Department of Internal Medicine, University of Pittsburgh Health Sciences Center.
1990 July-1992 June	Resident in Internal Medicine, Department of Internal Medicine, University of Pittsburgh Health Sciences Center
1992 July-1995 June	Fellow in Endocrinology and Metabolism, Division of Endocrinology and Metabolism, University of Pittsburgh Health Sciences Center.
1995 October-1997 October	Pharmacology Research Associate Training (PRAT) Fellow, National Institute of Neurological Disorders and Stroke, National Institutes of Health.
1997 October-1999 July	Intramural Research Training Associate (IRTA) Fellow, National Institute of Neurological Disorders and Stroke, National Institutes of Health

#### FACULTY APPOINTMENTS:

1999-2009 Instructor in Medicine, Harvard Medical School, Boston, MA

#### HOSPITAL OR OTHER PROFESSIONAL APPOINTMENTS:

1999 August-	Instructor, Division of Endocrinology-Diabetes-Hypertension, Department of Medicine, Brigham and Women's Hospital
1999 August-2000 July	Instructor, Division of Women's Health, Department of Medicine, Brigham and Women's Hospital
2000- 2006	Medical Staff, Department of Medicine, Faulkner Hospital

2000 February-2001	Staff physician, Program for Weight Management, Brigham and Women's Hospital and Faulkner Hospital
2001-2006 September	Medical Director, Program for Weight Management , Brigham and Women's Hospital and Faulkner Hospital
2006 October-	Division Head, Endocrinology, Diabetes, Bone and Mineral Disorders, Henry Ford Hospital
2006 October-	Whitehouse Chair of Endocrinology, Henry Ford Hospital
2006 October-2009	Service Chief, Endocrinology, West Bloomfield Hospital
2008-	Program Director, Endocrinology, and Metabolism Fellowship, Henry Ford Hospital

## **MAJOR PROFESSIONAL SOCIETIES:**

1990-	American College of Physicians, Fellow (2009)
1994-	American Association for the Advancement of Science, Member
1994-	The Endocrine Society, Member
1995-	American Federation of Medical Research, Chair Elect, Midwestern Section
1999-	American Diabetes Association, Member
2002-	The North American Association for the Study of Obesity, Member
2007	Association of Specialty Professors, Member
2009	Central Society of Clinical Research, selected 2009.

## **LICENSURE AND BOARD CERTIFICATION:**

1992	American Board of Internal Medicine, Internal Medicine
1995	American Board of Internal Medicine, Endocrinology, Diabetes, and Metabolism
1999	Massachusetts Registered Physician
2003	American Board of Internal Medicine, Internal Medicine
2005	American Board of Internal Medicine, Endocrinology, Diabetes, and Metabolism
2006	Michigan Registered Physician
2008	Lean Healthcare Certification, University of Michigan College of Engineering

## **HONORS/AWARDS:**

1986	Dean's Summer Research Fellowship, Columbia University College of Physicians & Surgeons
1995	American Federation of Clinical Research Trainee Investigator Award, American Federation of Clinical Research
2002	Society of Teaching Scholars, Brigham and Women's Hospital
2002-	K23 Mentored Patient-Oriented Research Career Development Award
2002-2003	Partners in Excellence Award for the Diabetes Management Service, Partners Healthcare
2003	Partners in Excellence Award for the Program for Weight Management, Partners Healthcare
2004-2007	ADA/NCQA Certificate of Recognition for Delivery of Diabetes Care, Other ADA/NCQA
2006-	Whitehouse Chair of Endocrinology
2008	Top Doctors Hour Detroit Magazine
2009	Fellowship, American College of Physicians
2009	Central Society of Clinical Research Selection

## **SERVICE:**

### **1. Patient care**

2000-2006 Obesity, Brigham and Women's Hospital

Clinical Activity Description: Medical Director of the Program for Weight Management

Patient Load: 4-7 new patients/ week and 8-12 follow-ups/ week. ; Moderate complexity

2000-2006 Endocrine., Brigham and Women's Hospital

Clinical Activity Description: Endocrinology and Diabetes Clinic, staff Endocrinologist, Brigham and Women's Hospital

Patient Load: 2-3 new patients/week and 4-8 follow-ups/week. ; Moderate to high complexity.

2000 Endocrine, Brigham and Women's Hospital

Clinical Activity Description: Diabetes in Pregnancy Program, Staff Endocrinologist

Patient Load: , 1-3 new patients/ week, 6-10 follow-ups/week; Moderate to High Complexity

2001-2006 Endocrine., Brigham and Women's Hospital

Clinical Activity Description: Diabetologist for the Islet Cell Transplant program at Brigham and Women's Hospital.

Patient Load: Two cases for 2003. ; Complexity High

2001-2006 Endocrine., Brigham and Women's Hospital

Clinical Activity Description: Diabetes Management Service, staff Endocrinologist

Patient Load: 25-50 follow-up patients on the inpatient surgical service, 10 weekends/year; Moderate to high complexity

2006- Endocrine, Henry Ford Hospital

Clinical Activity Description: Endocrinology Inpatient and Outpatient Clinical patients. Moderate to High Complexity

## **Journal/Editorial activity**

### **Editorial board memberships**

2008- Editorial Board, Diabetes Spectrum

### **National and international boards and committees**

#### **a. Positions held in professional associations**

2007 -2009 American Federation of Medical Research, Council Member Midwestern Section (2007-2010)

2008-2010 Research Affairs Committee, The Endocrine Society

2008- Glycemic Working Group for the ACCORD study

2008- HRQL Working Group for the ACCORD study

2009- 2010 American Federation of Medical Research, chair-elect Midwestern Section (2007-2010)

#### **b. Memberships/offices held in public agencies related to discipline**

2008- FDA Endocrinologic and Metabolic Drugs Advisory Committee, Member

### **State and local boards and committees**

2004 Partners Humans Subjects Research Committee (IRB), Member, Partners

2006- Medical Executive Committee, Henry Ford Hospital

2006- Inpatient Glycemic Control Committee, Henry Ford Hospital

2007-2009 West Bloomfield Hospital Service Chief Committee, Henry Ford Hospital

2007- West Bloomfield Hospital Wellness Center Committee, Henry Ford Hospital

2008- Henry Ford Hospital Contact Center Oversight Committee, Henry Ford Hospital

2008- Physician Referral Service Committee, Henry Ford Hospital

2008- Wayne State CTSA Committee  
 2008- Practice Affairs Committee, Henry Ford Hospital  
 2008-2009 Chair, Search Committee for Division Head for Hypertension  
 2009- Chair, Scientific Advisory Committee, Wayne State pre-CTSA

## TEACHING:

### Wayne State

3<sup>rd</sup> and 4<sup>th</sup> year medical students during medicine and/or endocrinology rotation at HFHS

Years at other colleges/universities

1993-1994 University of Pittsburgh Medical School, Physical Diagnosis for first and second year medical students  
 1994-1995 University of Pittsburgh Medical School, Preceptor for the problem based learning Endocrinology section of the Patho-Physiology course for 2nd year medical students  
 2000-2003 HMS Human Systems Module II-B Endocrine Multi-station  
 45 Medical Students 3 hours/year  
 2001-2006 Endocrinology and Diabetes Clinic  
 Preceptor 8 BWH Residents and 2 fellows/ year  
 2001-2006 Endocrinology and Diabetes Clinic  
 Preceptor 5 HMS Medical Students  
 2003 HMS Physiology Course, Endocrine section

### Advisees/Trainees

<i>Training Duration</i>	<i>Name</i>	<i>Current Position</i>
2000-2002	(b) (6)	Other Cardiology fellow
2001-2006		Other Cardiology Fellow
2002-2003		Other industry
2003-2006		Other Instructor in Surgery
2004-2006		Resident

### GRANT SUPPORT:

2000-2005 Consultant, N.I.H., A Randomized, Double-Blind, Placebo-Controlled Study of Rosiglitazone in HIV-Infected Subjects with Lipodystrophy  
 2000-2005 co-Investigator, N.I.H., SCOR: Genetics of Human Hypertension  
 2001-2004 co-Investigator, Company, (b) (4) Type II Diabetes Project  
 2002-2009 P.I., N.I.H., Cardiac Risk: Insulin Resistance, Hypertension, and PAI-1 K23 award  
 2006-2009 Site PI, N.I.H., ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES (ACCORD) \$2,431,231  
 2006-2009 Site PI, N.I.H., ACCORD-MIND – (substudy) \$8,9492  
 2007-2016 Site Co-PI, N.I.H., Epidemiology of Diabetes Interventions and Complications (EDIC) \$3,018,230  
 2006-2008 Co- PI, (b) (4) \$ (b) (4)  
 2006- Co-investigator, (b) (4) \$ (b) (4)  
 2006-2007 Co-investigator, (b) (4) \$ (b) (4)

2007-2008	P.I.,	(b) (4)	\$ (b) (4)
2007-2008	Co-investigator,		) – \$ (b) (4)
2007-	P.I.	\$	
2008	Co-investigator,	\$	
2008-2010	Co-investigator	\$	
2009-2010	Co-investigator	\$	

## PUBLICATIONS:

### Original Articles

1. Thomas A, Kim NB, Amico JA. Thyroidectomy does not alter hypothalamic oxytocin and vasopressin expression in chronically hypernatremic rats. *Life Sci.* 1995;57(4):403-10.
2. The Internal Medicine Research Consortium. Effect of Digital Rectal Examination on Serum Prostate-Specific Antigen in a Primary Care Setting. *Archives of Internal Medicine.* 1995;155(4):389-392.
3. Thomas A, Crowley RS, Amico JA. Effect of progesterone on hypothalamic oxytocin messenger ribonucleic acid levels in the lactating rat. *Endocrinology.* 1995;136(10):4188-94.
4. Thomas A, Amico JA. Sequential estrogen and progesterone (P) followed by P withdrawal increases the level of oxytocin messenger ribonucleic acid in the hypothalamic paraventricular nucleus of the male rat. *Life Sci.* 1996;58(19):1615-20.
5. Thomas A, Kim NB, Amico JA. Sequential exposure to estrogen and testosterone (T) and subsequent withdrawal of T increases the level of arginine vasopressin messenger ribonucleic acid in the hypothalamic paraventricular nucleus of the female rat. *J Neuroendocrinol.* 1996;8(10):793-800.
6. Thomas A, Kim NB, Amico JA. Differential regulation of oxytocin and vasopressin messenger ribonucleic acid levels by gonadal steroids in postpartum rats. *Brain Res.* 1996;738(1):48-52.
7. Amico JA, Thomas A, Hollingshead DJ, Kim NB. Administration of long-term estradiol and progesterone followed by progesterone withdrawal does not alter the plasma oxytocin secretory response to cholecystokinin or the pituitary oxytocin content in ovariectomized rats. *Endocr Res.* 1997;23(1-2):69-80.
8. Amico JA, Thomas A, Hollingshead DJ. The duration of estradiol and progesterone exposure prior to progesterone withdrawal regulates oxytocin mRNA levels in the paraventricular nucleus of the rat. *Endocr Res.* 1997;23(3):141-56.
9. Amico JA, Thomas A, Crowley RS, Burmeister LA. Concentrations of leptin in the serum of pregnant, lactating, and cycling rats and of leptin messenger ribonucleic acid in rat placental tissue. *Life Sci.* 1998;63(16):1387-95.
10. Thomas A, Kim DS, Fields RL, Chin H, Gainer H. Quantitative analysis of gene expression in organotypic slice-explant cultures by particle-mediated gene transfer. *J Neurosci Methods.* 1998;84(1-2):181-91.
11. House SB, Thomas A, Kusano K, Gainer H. Stationary organotypic cultures of oxytocin and vasopressin magnocellular neurones from rat and mouse hypothalamus. *J Neuroendocrinol.* 1998;10(11):849-61.
12. Thomas A, Shughrue PJ, Merchenthaler I, Amico JA. The effects of progesterone on oxytocin mRNA levels in the paraventricular nucleus of the female rat can be altered by the administration of diazepam or RU486. *J Neuroendocrinol.* 1999;11(2):137-44.
13. Korytkowski M, Thomas A, Reid L, Tedesco MB, Gooding WE, Gerich J. Glimepiride improves both first and second phases of insulin secretion in type 2 diabetes. *Diabetes Care.* 2002;25(9):1607-11.
14. Hadigan C, Yawetz S, Thomas A, Havers F, Sax PE, Grinspoon S. Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. *Ann Intern Med.* 2004;140(10):786-94.
15. Perlstein, TS, Gerhard-Herman, M, Hollenberg, NK, Williams, GH, Thomas, A. Insulin induces vasodilation, increases plasma renin activity, and sensitizes the renal vasculature to angiotensin receptor blockade in healthy subjects. *JASN.* 2007; 18: 944 - 951.

- 16 Goff DC, Gerstein HC, Ginsberg HN, Cushman WC, Margolis KL, Byington RP, Buse JB, Genuth S, Probstfield JL, Simons-Morton DG, The ACCORD Study Group. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: Current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. *Am J Cardiol.* 2007;99 (12):S4-S20.
- 17 ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Design and methods. Buse JB, The ACCORD Study Group. *Am J Cardiol.* 2007; 99 (12): S21-S33
- 18 Gerstein, HC, Riddle MC, Kendall DM, Cohen RM, Goland R, Feinglos MN, Kirk JK, Hamilton BP, Ismail-Beigi F, Feeney P, The ACCORD Study Group. Glycemia treatment strategies in the ACCORD trial. *Am J Cardiol.* 2007; 99 (12): S34-S43.
- 19 Cushman WC, Grimm RH, Cutler JA, Evans GW, Capes S, Corson MA, Sadler LS, Alderman MH, Peterson K, Bertoni A, Basile J, for the ACCORD Study Group. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. *Am J Cardiol.* 2007; 99 (12): S44-S55.
- 20 Ginsberg HN, Bonds DE, Lovato LC, Crouse JR, Elam MB, Linz PE, O'Connor PJ, Leiter LA, Weiss D, Lipkin E, Fleg JL, The ACCORD Study Group. Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. *Am J Cardiol.* 2007; 99 (12): S56-S67.
- 21 Kingry C, Bastien A, Booth G, Geraci TS, Kirpach B, Lovato LC, Margolis K, Rosenberg Y, Sperl-Hillen J, Vargo L, Williamson J, Probstfield JL, Recruitment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. The ACCORD Study Group. *Am J Cardiol.* 2007;99 (12): S68-S79.
- 22 Bonds DE, Kurashige EM, Bergenstal R, Brillon D, Domanski M, Felicetta J, Fonseca V, Hall K, Hramiak I, Miller ME, Osei K, Simons-Morton DG, The ACCORD Study Group. Severe hypoglycemia monitoring and risk management procedures in the ACCORD trial. *Am J Cardiol.* 2007; 99 (12): S80-S89.
- 23 Sullivan MD, Anderson RT, Aron D, Atkinson HH, Bastien A, Chen GJ, Feeney P, Gafni A, Hwang W, Katz L, Narayan KMV, Nwachuku C, O'Connor PJ, Zhang P, The ACCORD Study Group. Health-related quality of life and cost-effectiveness components of ACCORD: rationale and design. *Am J Cardiol.* 2007; 99 (12): S90-S102
- 24 Chew EY, Ambrosius WT, Howard LT, Greven CM, Johnson S, Danis R, Davis M, Genuth S, Domanski M, The ACCORD Study Group. Rationale, design and methods of the ACCORD Eye Substudy. *Am J Cardiol.* 2007; 99 (12): S103-S111
- 25 Williamson J, Miller ME, Bryan N, Lazar RM, Coker LH, Johnson J, Cukierman T, Horowitz KR, Murray A, Launer LJ, The ACCORD Study Group. The Action to Control Cardiovascular Risk in Diabetes-Memory in Diabetes (ACCORD-MIND) Substudy: rationale, design and methods. *Am J Cardiol.* 2007; 99 (12): S112-S122.
- 26 Hussam Al-Kateb,<sup>1</sup> Lucia Mirea,<sup>2,3</sup> Xinlei Xie,<sup>3</sup> Lei Sun,<sup>1,2</sup> Michelle Liu,<sup>1</sup> Hongtao Chen,<sup>1</sup> Shelley B. Bull,<sup>2,3</sup> Andrew P. Boright,<sup>4</sup> and Andrew D. Paterson<sup>1,2</sup> for the DCCT/EDIC Research Group\*. Multiple Variants in Vascular Endothelial Growth Factor (VEGFA) Are Risk Factors for Time to Severe Retinopathy in Type 1 Diabetes The DCCT/EDIC Genetics Study. *Diabetes* 56:2161–2168, 2007
- 27 James W. Albers, MD, PHD, William H. Herman, MD, MPH, Rodica Pop-Busui, MD, PHD, Catherine L. Martin, MS, Patricia Cleary, MS, Barbara Waberski, MS for the Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Intervention and Complications (EDIC) Research Group. Subclinical Neuropathy Among Diabetes Control and Complications Trial Participants Without Diagnosable Neuropathy at Trial Completion. Possible predictors of incident neuropathy? *Diabetes Care* 30:2613–2618, 2007
- 28 Carter RE, Lackland DT, Cleary PA, Yim E, Lopes-Virella MF, Gilbert GE, Orchard TJ; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group.  
Intensive treatment of diabetes is associated with a reduced rate of peripheral arterial calcification in the diabetes control and complications trial.  
*Diabetes Care.* 2007 Oct;30(10):2646-8.

- 29 Al-Kateb H, Boright AP, Mirea L, Xie X, Sutradhar R, Mowjoodi A, Bharaj B, Liu M, Bucks JM, Arends VL, Steffes MW, Cleary PA, Sun W, Lachin JM, Thorner PS, Ho M, McKnight AJ, Maxwell AP, Savage DA, Kidd KK, Kidd JR, Speed WC, Orchard TJ, Miller RG, Sun L, Bull SB, Paterson AD; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Multiple superoxide dismutase 1/splicing factor serine alanine 15 variants are associated with the development and progression of diabetic nephropathy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Genetics study. *Diabetes*. 2008 Jan;57(1):218-28.
- 30 Robert Y.L. Zee, Soren Germer, Abraham Thomas, Annaswammy Raji, Brian Rhees, Paul M Ridker, Klaus Lindpaintner, Gordon H. Williams, David M. Nathan, Mitchell Martin. C-Reactive Protein Gene Variation and Type 2 Diabetes Mellitus: A Case-Control Study. *Atherosclerosis*. 2008 Apr;197(2):931-6.
- 31 Lachin JM, Genuth S, Nathan DM, Zinman B, Rutledge BN; DCCT/EDIC Research Group. Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial--revisited. *Diabetes*. 2008 Apr;57(4):995-1001.
- 32 Brock JW, Jenkins AJ, Lyons TJ, Klein RL, Yim E, Lopes-Virella M, Carter RE; (DCCT/EDIC) Research Group, Thorpe SR, Baynes JW. Increased methionine sulfoxide content of apoA-I in type 1 diabetes. *J Lipid Res*. 2008 Apr;49(4):847-55.
- 33 Jaffa AA, Usinger WR, McHenry MB, Jaffa MA, Lipstiz SR, Lackland D, Lopes-Virella M, Luttrell LM, Wilson PW; the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Group. Connective Tissue Growth Factor and Susceptibility to Renal and Vascular Disease Risk in Type 1 Diabetes. *J Clin Endocrinol Metab*. 2008 May;93(5):1893-1900.
- 34 The Action to Control Cardiovascular Risk in Diabetes Study Group\*. Effects of Intensive Glucose Lowering in Type 2 Diabetes. *NEJM* vol. 358(24): 2545-59.
- 35 Ian H. de Boer; Bryan Kestenbaum; Tessa C. Rue; Michael W. Steffes; Patricia A. Cleary; Mark E. Molitch; John M. Lachin; Noel S. Weiss; John D. Brunzell; for the Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (**EDIC**) Study Research Group. Insulin Therapy, Hyperglycemia, and Hypertension in Type 1 Diabetes Mellitus *Arch Intern Med*, Sep 2008; 168: 1867 - 1873.
- 36 Gail Musen, Alan M. Jacobson, Christopher M. Ryan, Patricia A. Cleary, Barbara H. Waberski, Katie Weinger, William Dahms, Meg Bayless, Nancy Silvers, Judith Harth, Neil White, the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group. Impact of Diabetes and Its Treatment on Cognitive Function Among Adolescents Who Participated in the Diabetes Control and Complications Trial. *Diabetes Care* 2008 31: 1933-1938
- 37 Lopes-Virella, M, Carter, RE, Gilbert, GE, et al and the DCCT/EDIC Cohort Study\* Group. (2008). Risk factors related to inflammation and endothelial dysfunction in DCCT/EDIC cohort and their relationship with nephropathy and macrovascular complications: *Diabetes Care* 31:2006-2012.
- 38 Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group\* Prolonged Effect of Intensive Therapy on the Risk of Retinopathy Complications in Patients With Type 1 Diabetes Mellitus 10 Years After the Diabetes Control and Complications Trial. *Arch Ophthalmol*. 2008;126(12):1707-1715
- 39 Struan F.A. Grant, Hui-Qi Qu, Jonathan P. Bradfield, Luc Marchand, Cecilia E. Kim, Joseph T. Glessner, Rosemarie Grabs, Shayne P. Taback, Edward C. Frackelton, Andrew W. Eckert, Kiran Annaiah, Margaret L. Lawson, F. George Otieno, Erin Santa, Julie L. Shaner, Ryan M. Smith, Robert Skraban, Marcin Imielinski, Rosetta M. Chiavacci, Robert W. Grundmeier, Charles A. Stanley, Susan E. Kirsch, Daryl Waggott, Andrew D. Paterson, The DCCT/EDIC Research Group, Dimitri S. Monos, Constantin Polychronakos, and Hakon Hakonarson. Follow up analysis of genome-wide association data identifies novel loci for type 1 diabetes *Diabetes Publish Ahead of Print*, published online on October 7, 2008.

- 40 Linda M Delahanty, David M Nathan, John M Lachin, Frank B Hu, Patricia A Cleary, Georgia K Ziegler, Judith Wylie-Rosett, and Deborah J Wexler for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications. Association of diet with glycated hemoglobin during intensive treatment of type 1 diabetes in the Diabetes Control and Complications Trial. *Am J Clin Nutr* 2009;89:518–24.
- 41 Aruna V. Sarma, Alka M. Kanaya, Leroy M. Nyberg, John W. Kusek, Eric Vittinghoff, Brandy Rutledge, Patricia A. Cleary, Patricia Gatcomb, Jeanette S. Brown, Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Urinary Incontinence among Women with Type 1 Diabetes: How common is it? *Journal of Urology*, 2009, 181:1224-1230.
- 42 C.A. Czaja, B.N. Rutledge, P.A. Cleary, K. Chan, A.E. Stapleton, W.E. Stamm, Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Urinary Tract Infections in Women With Type 1 Diabetes Mellitus: Survey of Female Participants in the Epidemiology of Diabetes Interventions and Complications Study Cohort. *Journal of Urology*, 2009, 181:1129-1135.
- 43 Stephen K. Van Den Eeden, Aruna V. Sarma, Brandy N. Rutledge, Patricia A. Cleary, John W. Kusek, Leroy M. Nyberg, Kevin T. McVary, Hunter Wessells, and for the DCCT/EDIC Research Group. Effect of Intensive Glycemic Control and Diabetic Complications on Lower Urinary Tract Symptoms (LUTS) in Men With Type 1 Diabetes: Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. *Diabetes Care*, 2009, 32:664-670.
- 44 Aruna V. Sarma, Alka Kanaya, Leroy M. Nyberg, John W. Kusek, Eric Vittinghoff, Brandy Rutledge, Patricia A. Cleary, Patricia Gatcomb, and Jeanette S. Brown for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group Risk Factors for Urinary Incontinence Among Women With Type 1 Diabetes: Findings From the Epidemiology of Diabetes Interventions and Complications Study. *Urology* 2009. online April 10, 2009

### **Proceedings of Meetings**

1. Amico, J.A., Crowley, R.S., Insel, T.R., Thomas, A., and O'Keefe, J.A.. Effect Of Gonadal Steroids Upon Hypothalamic Oxytocin Expression. In: R. Ivell and J. Russell. *Oxytocin*; New York: Plenum Press;1995. p. 23-35.
2. Thomas A, Amico JA. Progesterone regulates hypothalamic oxytocin mRNA levels through gamma aminobutyric acid. In: *Adv Exp Med Biol*; ;1998. p. 123-5.

### **Reviews/Chapters/Editorials**

1. Thomas, A. and Verbalis, J.G. Hyponatremia and the Syndrome of Inappropriate Antidiuretic Hormone Secretion Associated with Drug Therapy in Psychiatric Patients. *CNS Drugs*. 1995;(4):357-369.
2. Thomas, A. and Dunaif, A. Polycystic ovary syndrome: a unique insulin resistance subphenotype. *Can J Diabetes Care*. 2000;24(4):47-55.
3. Dunaif A, Thomas A. Current concepts in the polycystic ovary syndrome. *Annu Rev Med*. 2001;52:401-19.
4. Thomas-Geevarghese, A and Thomas, A. Obesity, Lipids, and Cardiovascular Disease. In: *Cardiovascular Disease and Obesity*. Edited by Robinson, MK and Thomas. NY,NY: Taylor & Francis;2006.
5. Kolatkar, NS, Thomas, A, and Williams, GH. Hypertension and Obesity. In: *Cardiovascular Disease and Obesity*. Edited by Robinson, MK and Thomas, A. NY,NY: Taylor and Francis;2006.

### **Books, Monographs, and Textbooks**

1. In: *Cardiovascular Disease and Obesity*. Edited by Robinson, MK and Thomas, A. NY,NY: Taylor and Francis;2006.



## Educational Materials

1. Abraham Thomas, Kathryn Rexrode, Barbara Hodges, Jane Sillman, Mary Chapin, Kathy McManus, JoAnn Manson, Malcolm Robinson, and Soheyla Gharib. Obesity in Women. A Guide to Assessment and Management. 2003.
2. Abraham Thomas. The Endocrine Society Advocacy Tool on Insulin Resistance. 2005.

## PRESENTATIONS:

1. Invited and/or refereed international or national meetings

### *National/ International*

- |      |  |
|------|--|
| 2008 | The ACCORD Study. The Endocrine Society Annual meeting   |
| 2008 | The ACCORD Study- question and answer session. The Endocrine Society Annual Meeting.   |
| 2008 | Glycemic Control in Adults with Type 2 Diabetes. Cardiometabolic Risks CMR Phase II Conference. Muscat, Oman.                            |
| 2008 | The ADA/EASD Recommendations in 2008, how applicable? Cardiometabolic Risks CMR Phase II Conference. Muscat, Oman.                       |
| 2008 | Clinical Controversies in the Prevention and Management of Type 2 Diabetes. Cardiometabolic Risks CMR Phase II Conference. Muscat, Oman. |

2. Invited and/or refereed local/regional meetings

- |           |   |
|-----------|---|
| 2001-2002 | <u>Annual Intensive Review of Internal Medicine/obesity Lecture</u><br>Lecturer: 700 participants, 1 hours contact time per year, 8 hours prep time per year                                    |
| 2004-2005 | <u>Annual Intensive Review of Internal Medicine/obesity Lecture</u><br>Lecturer: 700 participants, 1 hours contact time per year, 8 hours prep time per year                                    |
| 1998      | Particle-mediated Transfection of Hypothalamic and Hippocampal Slice-Explant Cultures, University of Pittsburgh, Department of Biological Sciences  |
| 1998      | Hyponatremia: Evaluation and Treatment, Columbia University. Department of Rehabilitation Medicine Grand Rounds, Harlem Hospital Center   |
| 1998      | Particle-mediated Transfection of Hypothalamic and Hippocampal Slice-Explant Cultures, Catholic University, Department of Biological Sciences   |
| 1998      | Hyponatremia: Evaluation and Treatment, Michigan State University. Department of Medicine Grand Rounds  |
| 1998      | The Gene Gun: Transfection of Hypothalamic and Hippocampal Organotypic Slice-Explant Cultures, University of Illinois-Chicago Medical School, Department of Endocrinology Grand Rounds          |
| 1998      | The Gene Gun: Transfection of Hypothalamic and Hippocampal Organotypic Slice-Explant Cultures, Southern Illinois University School of Medicine- Springfield, Department of Endocrinology Rounds |
| 2000      | Hyponatremia: Evaluation and Treatment, Royal Free Hospital, UK, Division of Nephrology Conference.   |
| 2002      | Polycystic Ovary Syndrome, Lowell General Hospital, Lowell, MA, Hospital Grand Rounds   |
| 2004      | Obesity, Emerson Hospital. Grand Rounds   |
| 2006      | Inflammation, Salt, and the RAAS, University of Michigan, Division of Metabolism, Endocrinology and Diabetes  |
| 2006      | Inflammation, Salt, and the RAAS, Brigham and Women's Hospital, Endocrine Grand Rounds, Division of Endocrinology, Diabetes, and Hypertension   |
| 2007      | Inpatient and Outpatient Glycemic Control: Where are we and where are we going? Michigan Medical Center Symposium   |
| 2007      | Insulin Resistance and the Metabolic Syndrome, Great Lakes Symposium  |

2007	Insulin Resistance and the Metabolic Syndrome, Ingham Regional Medical Center and Michigan State University Symposium
2007	The Metabolic Syndrome, Women's Health Conference, Wyandotte Hospital
2008	Metabolic Disorders After Transplantation. Henry Ford Transplant Institute Conference
2009	Polycystic Ovary Syndrome AACE Michigan chapter Annual Meeting.

3. Invited seminars or lectures presented in last five years

2007	Obesity: An Increasing Epidemic, Henry Ford Hospital, Detroit, MI, Department of Medicine Medical Grand Rounds.
2007	Inpatient and Outpatient Glycemic Control, Henry Ford Hospital, Detroit, MI, Department of Anesthesiology Grand Rounds.
2008	Polycystic Ovary Syndrome, Dermatology Grand Rounds, Henry Ford Hospital
2008	Polycystic Ovary Syndrome, Ob/Gyn quarterly conference, Henry Ford Hospital
2008	ACCORD and other Studies. Division of General Medicine Conference, Henry Ford Hospital